{"disease":{"id":"myocardial-reinfarction-prevention","name":"Myocardial Reinfarction Prevention","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":11,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"apixaban","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eliquis","generic_name":"apixaban","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Factor Xa inhibitor","quality_score":85,"revenue":"14443","mechanism":"Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development."},{"drug_id":"ticagrelor","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brilinta","generic_name":"ticagrelor","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor [EPC]","quality_score":10,"revenue":"1100","mechanism":null},{"drug_id":"prasugrel","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effient","generic_name":"PRASUGREL","company_name":"Cosette","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor","quality_score":80,"revenue":"400","mechanism":"Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"myoinositol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"warfarin","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"propranolol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"clopidogrel","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"inositol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"lovastatin","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"metoprolol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"brilinta","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brilinta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}